Introduction

Creating a better future with R&D

Introduction

HEAL THE WORLD FOR A BETTER LIFE

Equipped with competitive R&D capacity and extensive experience in drug development, inno.N is working to perform further innovative research to create the next generation of healthcare products.

dna

DISEASE-FOCUS

Developing disease-focused & innovative medicines and biologicals

idea

OPEN INNOVATION

Accelerating R&D process and bringing positive outputs by open innovation

eye

DISTINGUISED TECHNOLOGIES

Blockbuster generic products and IMD products development

computer

PLATFORM
TECHNOLOGIES

Exporting technologies/products globally

inno.N R&D Center is expanding its research focus in accordance with the Center’s current research capabilities and platform technology. Our vision is to become a global bio-health company that can make a real impact on the world with tangible results. inno.N’s R&D Center continues to invest in more diverse research approaches that align with four main goals to achieve our mission, 'Heal the World for Better Life'.

2019

2019

Launched Korea's 30th new drug K-CAB Tab.
Launched Exone-R Tab., fixed-dose combination for hypertension with dyslipidemia Amlodipine / Valsartan / Rosuvastatin combination drug

2018

2018

'K-CAB‘Tab.(ingredient name: Tegoprazan)
in-house developed new drug for gastroesophageal reflux disease, has received a license from the Ministry of Food and Drug Safety
Korea’s No.30 New Drug

2018

2018

Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment) to NCPC GeneTech in China

2017

2017

Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment) to YL Biologics in Japan

2016

2016

Launched MACHKHAN, fixed-dose combination IMD for hypertension
ARB/CCB combination drug
First Candesartan / Amlodipine combination drug

2016

2016

New drug for Gastroesophageal acid reflux K-CAB Tab.(Tegoprazan)
P-CAB (Potassium -Competitive Acid Blocker) New Drug
Technology export to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China (2015)
New Drug Application (2017)

2014

2014

Launched VOGMET, fixed-dose combination IMD for Diabetes
α-glucosidase/biguanides combination drug
First Voglibose/Metformin combination drug

2013

2013

Launched EXONE, combination drug for hypertension
ARB/CCB combination drug
Valsartan / Amlodipine combination drug
Excellent optical (light) stability with differentiated technology

2012

2012

Selected as 'Innovative Pharmaceutical Company' accredited by Ministry of Health and Welfare
Accredited in Excellence in new drug R & D capability and overseas expansion capability

1998

1998

Launched EPOKINE, renal anemia treatment
Developed the first EPO(erythropoietin) in Korea and the third in the world

1995

1995

CITOPCIN injection Obtained domestic new technology certification, Won Chang Young-sil Award
Used the first in-vivo substance, TOF, in Korea

1992

1992

Launched CONDITION, a nationwide anti hangover drink
The first anti-hangover drink in Korea

1986

1986

Launched HEPACCINE-B, Hepatitis B vaccine
first-developed in Korea
World's 2nd hepatitis B vaccine HEPACCINE-B, obtained WHO certification (1993)

R&D Achievements

We are on our way to becoming a leading global pharmaceutical company.

2019

2019

Launched Korea's 30th new drug K-CAB Tab.
Launched Exone-R Tab., fixed-dose combination for hypertension with dyslipidemia Amlodipine / Valsartan / Rosuvastatin combination drug

2018

2018

'K-CAB‘Tab.(ingredient name: Tegoprazan)
in-house developed new drug for gastroesophageal reflux disease, has received a license from the Ministry of Food and Drug Safety
Korea’s No.30 New Drug

2018

2018

Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment) to NCPC GeneTech in China

2017

2017

Out licensed technology of second generation EPO 'CJ-40001' (a renal anemia treatment) to YL Biologics in Japan

2016

2016

Launched MACHKHAN, fixed-dose combination IMD for hypertension
ARB/CCB combination drug
First Candesartan / Amlodipine combination drug

2016

2016

New drug for Gastroesophageal acid reflux K-CAB Tab.(Tegoprazan)
P-CAB (Potassium -Competitive Acid Blocker) New Drug
Technology export to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China (2015)
New Drug Application (2017)

2014

2014

Launched VOGMET, fixed-dose combination IMD for Diabetes
α-glucosidase/biguanides combination drug
First Voglibose/Metformin combination drug

2013

2013

Launched EXONE, combination drug for hypertension
ARB/CCB combination drug
Valsartan / Amlodipine combination drug
Excellent optical (light) stability with differentiated technology

2012

2012

Selected as 'Innovative Pharmaceutical Company' accredited by Ministry of Health and Welfare
Accredited in Excellence in new drug R & D capability and overseas expansion capability

1998

1998

Launched EPOKINE, renal anemia treatment
Developed the first EPO(erythropoietin) in Korea and the third in the world

1995

1995

CITOPCIN injection Obtained domestic new technology certification, Won Chang Young-sil Award
Used the first in-vivo substance, TOF, in Korea

1992

1992

Launched CONDITION, a nationwide anti hangover drink
The first anti-hangover drink in Korea

1986

1986

Launched HEPACCINE-B, Hepatitis B vaccine
first-developed in Korea
World's 2nd hepatitis B vaccine HEPACCINE-B, obtained WHO certification (1993)